Business
Earth Science Tech, Inc. Receives a Price Target of $4.12 from Leading Independent Equity Research & Corporate Firm, SeeThruEquity
Earth Science Tech, Inc. Receives a Price Target of $4.12 from Leading Independent Equity Research & Corporate Firm, SeeThruEquity.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Hollywood, June 29, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCPINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices receives coverage initiation from SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, with a price target of $4.12.\n “We are honored to be covered by a well-respected Wallstreet equity firm, which took notice on our emerging trusted brand, Earth Science Tech, Inc. (OTC: ETST). Our team is passionate and truly believes in our brand. We truly believe ETST will emerge as a leading biotech, and most importantly, we plan to keep helping individuals to positively change and improve their lives.” Stated, Nickolas S. Tabraue, ETST’s President and COO.View full report: (here)Report Highlights: Large Market OpportunityCBD pharmaceuticals and nutraceuticals is one of the fasted growing sectors in the legal cannabis industry. Clinical research studies have demonstrated that CBD nutraceuticals have the potential to treat arthritis, MS, chronic pain, PTSD, depression, epilepsy and a myriad of other illnesses and disorders. The North American legal cannabis market stood at ~$7 billion in 2016, with strong growth prospects. The market is expected to reach ~$22 billion by 2020, representing a CAGR of 25%. Eight states in the US have legalized the use of recreational marijuana (cannabis), while 29 states allow marijuana to be used for medicinal purpose. We believe favorable regulatory environment will provide further tailwind to ETST. However, recent stance by DEA that it considers CBD as a Schedule 1 substance has created some overhang.Strong Product Pipeline to Fuel Growth                                                      The product pipeline remains robust with series of CBD based nutraceutical, supplements as well pharmaceutical products anticipated to be launched in 2017 and early 2018. The pipeline comprises three sports supplements to be launched in 2017, two CBD based pharmaceuticals drugs to be launched in 1Q/2Q18, new e-liquid and ...